Table 1.

Baseline Characteristics and Outcome in All Patients With Staphylococcus aureus Bacteremia

	Prolonged IV Antibiotic Treatment (n = 45)	IV-Oral Switch (n = 61)	P
Male, n (%)	27 (60.0)	44 (72.1)	.193
Mean age, years	61.4	58.9	.926
Charlson comorbidity index	3.8	3.3	.446
Community acquisition, n (%)	19 (42.2)	28 (45.9)	.883
Persistent fever (>72 hours), n (%)	27 (60.0)	24 (39.3)	.043
Persistent positive blood cultures (>48 hours), n (%)	25 (55.6)	14 (22.9)	.001
Signs of infection >48 hours before start of adequate therapy, n (%)	20 (44.4)	26 (42.6)	.832
MRSA, n (%)	2 (4.4)	2 (3.3)	1.000
Metastatic infection, n (%)
Vertebral osteomyelitis	14 (31.1)	9 (14.8)	.044
Nonvertebral osteomyelitis	7 (15.6)	16 (26.2)	.091
Infected osteosynthesis	3 (6.7)	11 (18.0)	.089
Arthritis	12 (26.7)	11 (18.0)	.291
Prosthetic joint infection	5 (11.1)	7 (11.5)	.954
Splenic abscess	0	2 (3.3)	.224
Soft tissue abscess	25 (55.6)	33 (54.1)	.883
Pulmonary foci	17 (37.8)	12 (19.7)	.039
Total, n	83	101
Relapse	0	0
3-Month mortality, n (%)	6 (13.3)	4 (6.6)	.242
Drainage, radiologically or surgically, n (%)	26 (57.8)	31 (50.1)	.666
Hospital admission duration, median (IQR), days	29 (33)	17 (11)	.001
Treatment duration, median (IQR), days	45 (44)	45 (49)	.355
Addition of rifampicin, n (%)	15 (33.3)	16 (26.2)	.643
Adverse events,a n (%)	25 (55.6)	30 (49.2)	.516
Phlebitis	16 (35.6)	24 (39.3)	.691
Central venous line–related infection	0	1 (1.6)	1.000
Central venous line–related thrombosis	0	0
Rash	1 (2.2)	1 (1.6)	1.000
Acute kidney injury	6 (13.3)	2 (3.3)	.069
Nausea/vomiting	1 (2.2)	2 (3.3)	1.000
Clostridiodes difficile infection	2 (4.4)	0
Increased liver enzymes	3 (6.7)	0

Abbreviations: IQR, interquartile range; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus.

^aIn 4 patients, more than 1 adverse event occurred.